MBX Biosciences (MBX) Profit After Tax (2023 - 2026)

MBX Biosciences has disclosed Profit After Tax across 4 years of filings, most recently posting -$23.5 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$23.5 million, up 1.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.6 million (down 17.94% YoY), and the FY2025 annual result was -$87.0 million, down 40.55% from the prior year.
• Profit After Tax came in at -$23.5 million for Q1 2026 at MBX Biosciences, down from -$22.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$8.8 million in Q4 2023 to a low of -$23.9 million in Q1 2025.
• The 4-year median for Profit After Tax is -$18.1 million (2024), against an average of -$17.4 million.
• Across the five-year window, Profit After Tax sank 93.56% in 2025 and gained 1.59% in 2026, its largest moves.
• MBX Biosciences' Profit After Tax stood at -$8.8 million in 2023, then sank by 76.0% to -$15.6 million in 2024, then slumped by 41.94% to -$22.1 million in 2025, then slipped by 6.38% to -$23.5 million in 2026.
• The last three Profit After Tax figures came in at -$23.5 million (Q1 2026), -$22.1 million (Q4 2025), and -$21.6 million (Q3 2025), per Business Quant data.